Royce & Associates LP Has $38.91 Million Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Royce & Associates LP decreased its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 7.8% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,864,351 shares of the biopharmaceutical company's stock after selling 156,754 shares during the period. Royce & Associates LP owned about 1.56% of Catalyst Pharmaceuticals worth $38,909,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. JPMorgan Chase & Co. increased its stake in shares of Catalyst Pharmaceuticals by 9.1% during the third quarter. JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company's stock worth $8,116,000 after purchasing an additional 33,888 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in Catalyst Pharmaceuticals by 13.9% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 417,332 shares of the biopharmaceutical company's stock valued at $8,710,000 after purchasing an additional 50,888 shares during the period. Wellington Management Group LLP acquired a new position in shares of Catalyst Pharmaceuticals during the 3rd quarter worth approximately $1,185,000. Redhawk Wealth Advisors Inc. acquired a new position in shares of Catalyst Pharmaceuticals during the 4th quarter worth approximately $1,273,000. Finally, Spire Wealth Management grew its position in shares of Catalyst Pharmaceuticals by 1,342.9% during the 4th quarter. Spire Wealth Management now owns 14,429 shares of the biopharmaceutical company's stock worth $301,000 after purchasing an additional 13,429 shares in the last quarter. Institutional investors own 79.22% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Several research firms have recently issued reports on CPRX. Baird R W raised Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Monday, February 3rd. Bank of America reissued a "buy" rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. StockNews.com raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. Stephens reissued an "overweight" rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Finally, Robert W. Baird upped their target price on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research note on Monday, March 3rd. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Catalyst Pharmaceuticals has an average rating of "Buy" and a consensus price target of $32.50.

Catalyst Pharmaceuticals Stock Up 2.5 %

Shares of NASDAQ CPRX traded up $0.56 during midday trading on Thursday, reaching $23.16. 1,144,092 shares of the company were exchanged, compared to its average volume of 1,044,205. Catalyst Pharmaceuticals, Inc. has a one year low of $14.47 and a one year high of $24.64. The stock has a market cap of $2.81 billion, a P/E ratio of 19.63, a PEG ratio of 3.31 and a beta of 0.84. The stock's 50-day moving average price is $22.34 and its 200-day moving average price is $21.57.

Insider Activity

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,904 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the transaction, the insider now directly owns 68,873 shares in the company, valued at approximately $1,521,404.57. This represents a 39.47 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the transaction, the insider now owns 188,564 shares in the company, valued at approximately $4,333,200.72. This trade represents a 25.04 % decrease in their position. The disclosure for this sale can be found here. Insiders own 11.00% of the company's stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.